안녕하세요 CND 센터 관리자입니다. 

오늘은 in vitro 강연 시리즈 중 '약물 유도성 미토콘드리아 독성을 평가하기 위한 in vitro screening tools의 발전'을 주제로 한 강연을 소개해 드립니다.
영상자료 대신 발표 PPT를 파일로 첨부하였습니다. 
부디 많은 참고 되시길 바랍니다.

Yvonne Will
Pfizer, Inc., San Diego, California

It is estimated that only 50% of the animal studies predict human efficacy and more importantly human toxicity. In addition, the use of animals should be minimized as much as possible for ethical reasons. Today, there are vigorous, ongoing national and international research and policy efforts to develop alternatives to animal testing. The efforts focus on both in vitro and in silico approaches and methods. For example, the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS) created the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) in 1998.

Mitochondrial dysfunction is a common mechanism of drug-induced toxicity for a variety of therapeutics, such as certain antiviral drugs, lipid-lowering drugs, NSAIDs and certain cancer chemotherapeutics. Therefore, the early identification of drug candidates that potentially disrupt mitochondrial function is of significant importance in drug discovery. In the past few years we have developed organelle and cell based in vitro screens to detect potential mitochondrial toxicities. These include oxygen sensors to measure mitochondrial respiration in isolated mitochondria and cells, immunocapture of individual electron transport chain proteins that can identify inhibitors of mitochondrial electron transport, and metabolic profiling using oxygen and pH measurements. We discuss the strength and limitations of new applicable high throughput screens and provide recommendations of where to position these assays within the drug development process.

 

출처: SOT (Society of Toxicology) http://www.toxicology.org/education/pw/ivLectures.asp